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Abstract: Saliva is a complex body fluid that comprises secretions from the major and  
minor salivary glands, which are extensively supplied by blood. Therefore, molecules  
such as proteins, DNA, RNA, etc., present in plasma could be also present in saliva.  
Many studies have reported that saliva body fluid can be useful for discriminating several 
oral diseases, but also systemic diseases including cancer. Most of these studies revealed 
messenger RNA (mRNA) and proteomic biomarker signatures rather than specific non-coding 
RNA (ncRNA) profiles. NcRNAs are emerging as new regulators of diverse biological 
functions, playing an important role in oncogenesis and tumor progression. Indeed, the small 
size of these molecules makes them very stable in different body fluids and not as susceptible 
as mRNAs to degradation by ribonucleases (RNases). Therefore, the development of  
a non-invasive salivary test, based on ncRNAs profiles, could have a significant applicability 
to clinical practice, not only by reducing the cost of the health system, but also by benefitting 
the patient. Here, we summarize the current status and clinical implications of the ncRNAs 
present in human saliva as a source of biological information. 
OPEN ACCESS
Int. J. Mol. Sci. 2015, 16 8677 
 
 
Keywords: saliva; liquid biopsy; body fluid; disease; diagnostics; non-invasiveness; 
biomarkers; non-coding RNA (ncRNAs); small ncRNAs; long ncRNAs 
 
1. Introduction: Saliva as a Liquid Biopsy 
Saliva comes primarily from three major paired salivary glands (parotid, submandibular and 
sublingual) where specialized cells take up water, salts and macromolecules from the blood that add up 
to their individual gland secretions. Hence, most compounds found in blood are also present in saliva, 
which has recently been termed the “mirror of the body” [1,2]. Upon release of glandular secretions into 
the oral cavity, the fluid is mixed with a variety of exocrine, non-exocrine, cellular, and exogenous 
components to ultimately form whole saliva (WS). Saliva has a critical role in maintaining the oral  
health and homeostasis, and the function of the upper gastrointestinal tract. The content of saliva is 
mostly water but it also contains molecules (posttranslationally modified proteins (e.g., glycoproteins, 
phosphoproteins), peptides, lipids, minerals, and other small compounds) that lubricate our tongues, 
thereby facilitating the chewing, speaking and swallowing processes, preventing excessive swings in pH, 
and beginning the process of digestion [3,4]. Furthermore, saliva protects the oral cavity from foreign 
invaders, such as bacteria and viruses, by digestion and inhibition of their growth. Unfortunately, the 
importance of saliva is often appreciated only when it is gone, as commonly happens in patients with 
oral cancer or undergoing radiation treatments [5]. 
Saliva is a highly desirable body fluid for biomarker development, as it provides a non-invasive, 
simple and low-cost method for disease detection and screening [6–8]. Many efforts have been made  
in elucidating the molecular profiles in healthy saliva, both at protein and messenger RNA (mRNA) 
levels [9]. The overall low concentration of saliva markershindered the development of salivary 
biomarkers over the last decade. Continuous technological advancements, however, have allowed the 
performance of high-throughput strategies that overcome this problem. The use of several proteomic 
techniques, such as 2-D gel electrophoresis, mass spectrometry and Western blot, were used to define 
the salivary proteome [10–14]. The use of transcriptomic techniques, such as quantitative PCR 
(qPCR), microarray analysis and deep sequencing analysis have permitted the definition of the salivary 
transcriptome [15–21], thereby contributing to the foundation of salivary biomarker development.  
In addition, the salivary microbiome [22] and metabolome [23–25] have also been determined and 
shown a promising potential as disease-related biomarkers for oral and systemic diseases [22]. The 
vast amount of “salivaomics” data has led to the development of the the Salivaomics Knowledge  
Base (SKB) [26], a data management system and Web resource supporting salivary diagnostics 
research [27,28]. In addition to salivary content, a great deal of effort has been made to standardize 
procedures for saliva collection, storage and analysis [29–31], in addition to methods to increase the 
stability of the proteins and mRNAs present in saliva [32–35]. 
Although saliva fulfills the goal of the holy grail of diagnostics—non-invasiveness—salivary 
diagnostics is as of yet only recognized for oral diseases; its clinical utility and scientific credibility  
for systemic diseases is still unsubstantiated. The potential use of saliva has been demonstrated not 
only for detecting various local diseases, including Sjögren’s syndrome [36–38], oral and head and neck 
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cancers [39–43], but also for detecting systemic diseases, such as HIV [44–46], hepatitis C virus [47–50], 
type 2 diabetes [51], insulin resistance [52], cardiovascular diseases [53,54], lung cancer [55–57], 
resectable pancreatic cancer [58,59], breast cancer [60,61] and ovarian cancer [62]. 
After a decade of scientific and technological advancements, the incipient maturation of these basic 
and translational outcomes is leading to the development of clinical tests that benefit patients, based on 
the use of saliva as a source of biological information. Nonetheless, the majority of all these  
efforts have been focused on revealing the presence of mRNA and proteins as powerful diagnostic 
biomarkers, but little is known about the emerging new class of non-coding RNAs (ncRNAs) in saliva 
body fluid. Here, we review the current status, power, advantages, and future applications of ncRNAs 
in saliva as a source of biological information, disease status, and biomarker performance. 
2. Salivary Non-Coding RNAs Associated with Physiological and Pathological States 
Around 98% of all transcriptional output in humans is non-coding. RNA-mediated gene regulation is 
widespread in higher eukaryotes and complex genetic phenomena like RNA interference, co-suppression, 
transgene silencing, imprinting, methylation, and possibly position-effect variegation and transvection; 
these are all involved in intersecting pathways based on or connected to RNA signaling [63,64]. Although 
proteins are the fundamental effectors of cellular function, the basis of eukaryotic complexity and 
phenotypic variation may lie primarily in a controlled architecture composed of a highly parallel system 
of trans-acting RNAs: the ncRNAs [63]. The ncRNAs are short RNAs that have been widely described 
as being stable in many body fluids [65], ostensibly protected from RNA degradation and therefore 
appearing to be potential biomarkers. The classification of ncRNAs is based on the transcript size: 
small ncRNAs (<200 bp)—including micro RNAs (miRNAs)—and long ncRNAs (≥200 bp) [63,66,67]. 
ncRNAs are emerging as new regulators of diverse physiological functions. Importantly, ncRNA 
deregulation, together with other molecular defects, plays an important role in oncogenesis and tumor 
progression [68–70]. Thus, ncRNAs are very appealing for the development of new target therapies and 
appear to be important for the discovery of new disease-specific diagnostic makers in body fluids, 
including saliva. 
A complex compositional profile of saliva extracellular RNA (exRNA) has emerged, encompassing 
mostly mRNAs, but also ncRNAs such as microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), 
and other non-coding RNAs [21,71,72]. However, despite the large amount of existing data, the entire 
spectrum of saliva exRNA has not been fully elucidated, thus warranting the need for further 
comprehensive deciphering analysis. Interestingly, by using high-throughput RNA sequencing (RNA-Seq) 
and powerful bioinformatic platforms, the landscape of miRNA, piwi-interacting RNA (piRNA) and 
circular RNA (circRNA) present in human saliva has been described, which represents a new source of 
interesting biomarkers [73]. In addition, there is also increasing interest in understanding the functional 
aspects of salivary exRNA in oral and systemic biology [55,59]. Such studies will be facilitated by  
a detailed delineation of the landscape of salivary exRNA. 
2.1. Characterization of Salivary Non-Coding RNAs 
Compared with other biofluids, saliva can be collected easily and non-invasively. However, low 
RNA abundance, small sample volumes, highly fragmented mRNA, and high abundance of bacterial 
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content create challenges for downstream RNA sequencing analyses [21]. Thus, ncRNAs rise to the 
first position of ideal and suitable salivary biomarkers because of its short size, body fluid stability, 
and their main location inside the exosomes [59,65,72,74]. 
Among all ncRNAs, small ncRNAs are the most exploited and widely described ncRNAs in saliva, 
particularly miRNAs, which are small, 19- to 23-nucleotide-long single-stranded RNA molecules. 
miRNAs play an important role in regulating various biological processes through their interaction 
with cellular mRNA [75], and have been broadly characterized in saliva body fluid. Weber et al. [76], 
with the goal of assessing the distribution of miRNAs and demonstrating the potential use of miRNAs 
as biomarkers, examined the presence and distribution of miRNAs in 12 human body fluids, including 
saliva. They found that miRNAs were present in all the tested body fluids. Moreover, they noticed that 
several of the highly abundant miRNAs were common among multiple fluid types, and some of the 
miRNAs were enriched in specific body fluids. Interestingly, saliva, breast milk, and seminal fluid had 
a higher number of detectable miRNA species, whereas urine, cerebrospinal fluid, and pleural fluid 
had far fewer. When comparing the miRNA spectrum found in plasma with that from most of the other 
body fluids, they found important differences, thus indicating an extensive “blood filtering” process 
that takes place in most body fluids, including saliva. Other discrepancies can be explained by the 
differential uptake or release of miRNAs from varying circulating cell types that come in contact with 
the blood, or other processes not yet fully understood. 
Different groups have studied the miRNA composition of the WS, including the cell content, cell 
debris and bacteria present in oral cavity. Patel et al. [77] described miR-223, miR-191, miR-16, miR-203, 
and miR-24 as the five most abundantly expressed miRNAs; they have also been reported in other  
studies [74,78,79]. Additionally, the improvement of the RNA isolation method increased the recovery of 
high quality RNA, allowing the detection of many previously undetected miRNAs. Spielmann et al. [21] 
compared the RNA from unstimulated whole saliva (WS) and cell-free saliva (CFS) by using RNA-Seq 
analysis. They found that more than 90% of the uniquely mapped genes were coding (i.e., mRNAs), and 
the remaining percentage was comprised of ncRNAs. However, ranking the genes by RPKM (reads 
per kilobase per million) criteria revealed that 95 out of the top 100 highly expressed genes encode for 
ncRNAs, most of them classified being as small nucleolar RNAs (snoRNAs). Furthermore, they found 
measurable differences between CFS and WS; remarkably, a higher fraction of microbial RNA was found 
in WS compared to CFS, which markedly decreased the sensitivity of human RNA in WS analysis. 
Therefore, these data suggest that a low-speed centrifugation step reduced the presence of microbial 
RNA. Adding subsequent steps might therefore remove more of the microbial cells and cell debris. 
Recently, Bahn et al. [73], by using high-throughput RNA-Seq, conducted an in-depth bioinformatic 
analysis of ncRNAs found in human CFS from healthy individuals, with special focus on miRNAs, 
piRNAs, and circRNAs. Their data demonstrated robust reproducibility of miRNA and piRNA profiles 
across individuals. Furthermore, individual variability of these salivary exRNA species was highly 
similar to those RNAs found in other body fluids or intracellular samples, despite the direct exposure of 
saliva to environmental impacts. By comparative bioinformatics analysis of more than 90 RNA-Seq 
datasets of different origins, they demonstrated that piRNAs were surprisingly abundant in CFS 
compared with other body fluid or intracellular samples; with expression levels in CFS comparable to 
those found in embryonic stem cells and skin cells. In other words, the most abundant types of small 
ncRNAs codified for human piRNAs (7.5% of reads), miRNAs (6.0% of reads) and snoRNAs (0.02% of 
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reads). In addition, 58.8% of reads corresponded to microbial RNA sequences, reflecting the enriched 
presence of microorganisms in saliva [21]. Furthermore, using a customized bioinformatics method, 
more than 400 circRNAs were found in CFS. These data represent the first global characterization and 
experimental validation of circRNAs in any type of body fluid [73]. 
2.2. Salivary Exosomes as a Source of Non-Coding RNAs 
In an effort to avoid microbial and intracellular RNA contamination, some groups have started to 
investigate the miRNA content in extracellular vesicles (EVs) isolated from saliva. EVs, commonly 
known as exosomes, are small membrane vesicles measuring approximately 30 to 100 nm in diameter 
that carry different molecules—such as proteins, lipids, as well as mRNA and ncRNAs—released from 
the cell of origin to the microenvironment [80–82]. Body fluid-derived EVs are a mixture of vesicles 
originating from different types of cells: both cells found in the body fluids and/or the cells lining the 
cavities of extruded body fluids [83,84]. 
Increasing evidence suggests that RNAs are not passively loaded into EVs, but that certain populations 
of RNAs become enriched in EVs compared to parental cells, mainly because of a size restriction, but 
also because of the existence of an active sorting mechanism that occurs at the RNA level [85]. For 
instance, in cancer development, the release of nucleic acids into the blood seems to be related to the 
apoptosis and necrosis of cancer cells in the tumor microenvironment; it is also the result of secretion. 
Circulating RNAs are detectable in the serum and plasma of cancer patients, and are surprisingly stable 
in spite of the fact that high amounts of RNases circulate in the blood of those patients. This somehow 
implies that RNA may be protected from degradation by its packaging into EVs [65]. 
At least for some cell types, miRNAs may be transferred within EVs to neighboring cells, where  
they alter the gene expression and phenotype of the recipient cells. Moreover, accumulating evidence 
indicates that the incorporation of miRNAs into EVs allows those miRNAs to circulate in the body 
fluids while avoiding degradation from RNAse activity. The type and content of salivary EVs suggest 
that saliva-derived EVs are mainly from epithelial cells and granulocyte origin [86]. Two types of EVs 
have been identified in saliva: one population that is heterogeneous in their size (30–250 nm), and one 
population that is homogeneous in their size (20–80 nm) [87]. 
Currently, EVs isolation is time consuming and therefore it is difficult to consider analyzing 
salivary EVs for clinical routine. Despite this practical consideration, salivary EVs represent a better 
method to characterize the exRNA present in saliva. In 2010, Michael et al. [74], successfully isolated 
EVs from human saliva; however, they pointed out that WS viscosity and cellular contamination made 
it less than ideal for EV characterization. Although several studies have been focused on characterizing 
salivary EVs at nanostructural, transcriptomic [88,89], and proteomic [90] levels, little is known about 
ncRNA content in salivary EVs. Gallo et al. [91] investigated whether body fluid miRNAs are 
circulating freely or encapsulated into EVs. They compared the miRNA purified from isolated EVs 
and the miRNA purified from EV-depleted supernatant, from both serum and saliva body fluids. They 
found a lower miRNA concentration in salivary EVs than in serum EVs, but still a predominant 
presence of miRNA in the EVs fraction compared to EV-depleted salivary supernatant. Later on,  
Ogawa et al. [72] investigated the content of small ncRNAs from salivary EVs (two type of salivary 
EVs were investigated) and from WS, by using RNA-seq technology. They found that many types of 
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small RNA, such as miRNA, piRNA, snoRNAs and other small ncRNAs, are contained in salivary EVs. 
A total of 143 miRNAs were common in both salivary EVs and WS, while 147 miRNAs were only 
detected in EVs. Importantly, piRNA and snoRNAs were first described in saliva samples: 129 piRNAs 
were mostly expressed in salivary EVs, while in WS they only found 90 piRNAs. Furthermore, the 
number of snoRNAs detected in one EV fraction was less than 50% than in the other EV fraction and 
WS. Thus, specific ncRNAs appear differentially expressed in WS, depleted or non-depleted EV fraction, 
and further studies are needed to define the function of small ncRNAs in salivary EVs. 
2.3. Salivary Non-Coding RNAs as a Source of Biomarkers for Local and Systemic Diseases 
The identification of biological markers for specific diseases is a major impetus in current research. 
An ideal diagnostic biomarker should enable unbiased determination of the disease, especially in  
patients with early stage disease and without specific symptoms. A good biomarker should fulfill 
several criteria, such as high specificity, high sensitivity, easy use, standardized protocols, and 
readability of the results for the clinicians. Theoretically, every disease may be detected and 
characterized by its unique biomarker. However, a more complete view for a biomarker is a panel of 
up- and down-regulated molecules that differ in their disease and normal states [92]. 
Human saliva has been increasingly used for biomarker development to enable non-invasive 
detection of diseases. The term “salivaomics” was coined to highlight the omics constituents in saliva 
that can be used for biomarker development and personalized medicine [28]. Salivary exRNA [21] was 
discovered 10 years ago; since then, the nature, origin, and characterization of salivary exRNA have 
been actively pursued [17,21,36,40,58]. These studies have demonstrated the potential use of salivary 
exRNA not only to detect local diseases but also systemic diseases. However, there is a small grouping 
of studies that reveal ncRNAs as a source of diagnostic biomarkers in saliva either for local or 
systemic diseases (Table 1). 
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Table 1. Salivary ncRNAs as disease-related molecular markers. 
Ref. Study Saliva Fraction Disease Study Cohort Technique Molecular Profile 
Characterization 
[76] 
Weber et al.,  
Clin. Chem. 2010 
CFS characterization 5 healthy donors 
Human miScript Assay panel 
(Qiagen)—714 miRNA 
miR-182*, miR-450b-5p, miR-622, miR-141,  
miR-26a, miR-145*, miR-135b*, miR-381,  
miR-96*, miR-1228, miR-431* 
[74] 
Michael et al.,  
Oral Dis. 2010 
exosomes characterization 2 healthy donors 
miRCURY LNA microRNA 
Array, v.10.0, (Exiqon, Denmark) 
let-7b, let-7c*, miR-128, miR-150*, miR-17,  
miR-1908, miR-212, miR-27b*, miR-29b,  
miR-29c, (Top-10) 
[77] 
Patel et al.,  
Arch Oral Biol. 2011 
WS characterization 20 healthy donors 
TaqMan1 Low Density Array 
Card (TLDA) Human miRNA 
Panel v2.0 (Applied Biosystems) 
miR-223, miR-191, miR-16, miR-203,  
and miR-24 
[21] 
Spielmann et al.,  
Clin. Chem. 2012 
CFS and WS characterization 8 healthy donors 
SOLiDTM Total RNA-Seq Kit 
and Barcoding Kit (modules 1–16) 
(Applied Biosystems) 
224 snoRNAs 
[91] 
Gallo et al.,  
PLoS ONE 2012 
exosomes characterization 
Healthy donors  
(# N/A) 
TaqMan MicroRNA Assay, PN 
4427975, Applied Biosystems 
miR-22, miR202, miR-203, miR-1273d 
[72] 
Ogawa et al.,  
Biol. Pharm. Bull. 2013 
exosomes  
and WS 
characterization 
1 healthy donor  
(7 saliva collection 
replicates) 
Illumina Genome Analyzer Iix  
by Hokkaido System Sciences 
Co., Ltd. (Japan) 
miR-378a, miR-143, let-7c, miR-146b, miR-21, 
let-7f-1, let-7f-2, miR-30a, miR-9-1, miR-9-2, 
miR-9-3, let-7a-1, let-7a-2, miR-20a, miR-30d, 
miR-30e; piR-39980, piR-48209, piR-52207, 
piR-38581, piR-36095, piR-59293, piR-61648, 
piR-55361; U78, U44, U21, U31, U104,  
U15A, snR39B 
[73] 
Bahn et al.,  
Clin. Chem. 2014 
CFS characterization 8 healthy donors Illumina HiSeq 50SE 
127–418 miRNAs (Top-2: miR-223-3p and 
miR-148a-3p) 
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Table 1. Cont. 
Ref. Study Saliva Fraction Disease Study Cohort Technique Molecular Profile 
Local & Systemic Diseases 
[78] 
Park NJ et al.,  
Clin. Cancer Res. 2009 
CFS and WS 
oral squamous 
cell carcinoma 
50 OSCC patients and  
50 healthy matched controls 
RT-preamp-qPCR miR-125a and miR-200a 
[93] 
Wiklund et al.,  
PLoS ONE 2011 
WS 
oral squamous 
cell carcinoma 
15 OSCC patients and  
7 healthy controls 
TaqManH qRT-PCR assays 
(Applied Biosystems) 
miR-375 and miR-200a expression and  
miR-200c-141 methylation 
[94] 
Liu CJ et al.,  
Head Neck 2012 
CFS 
oral squamous 
cell carcinoma 
45 oral carcinoma, 10 oral 
verrucous leukoplakia, and 
24 healthy controls 
TaqMan miRNA assay 
system (Applied Biosystems, 
Foster City, CA, USA) 
miR-31 
[95] 
Matse et al.,  
Clin. Cancer Res. 2013 
WS 
paratiroid gland 
tumors 
38 malignant tumors and  
29 benign parotid  
gland tumors 
TaqMan Human MicroRNA 
Cards (Applied Biosystems) 
and RTqPCR 
hsa-miR-132, hsa-miR-15b, mmu-miR-140, 
and hsa-miR-22 
[96] 
Tang et al.,  
Mol. Med. Rep. 2013 
SP 
oral squamous 
cell carcinoma 
4 OSCC saliva samples and 
12 healthy controls 
RT-qPCR of six lncRNAs 
found in OSCC tissue 
MALALT-1, HOTAIR 
[97] 
Wang et al.,  
Biosens. Bioelectron. 2013 
CFS 
oral squamous 
cell carcinoma 
5 artificial saliva samples 
(spiked) 
Novel home-made 
electrochemical biosensor 
magnetic-controllable  
gold electrode 
miR- 200a, miR-142-3p, miR-93 and  
miR-125a 
[98] 
Xie Z et al.,  
PLoS ONE 2013 
CFS and WS 
esophageal 
squamous  
cell carcinoma  
NA Agilent miRNA microarray miR-144, miR-10b*, miR-21 and miR-451 
[99] 
Yang et al.,  
BMC Cancer 2013 
SP 
oral squamous 
cell carcinoma 
7 non-progressing LGD,  
8 progressing LGD  
into OSCC and  
7 healthy controls 
The TaqManW low density 
array (TLDA) qRT-PCR 
system (Applied Biosystems, 
Foster City, CA, USA) 
miR-10b, miR-660, miR-708, miR-30e,  
miR-145, miR-99b, miR-181c and miR-197 
[100] 
Salazar et al.,  
Cell Oncol. 2014 
WS 
head and  
neck cancer 
61 HNSCC patients and  
61 healthy controls 
miScriptTM miRNA 
microarray, RTqPCR, TCGA 
miR-9, miR-134 and miR-191 
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Table 1. Cont. 
Ref. Study Saliva Fraction Disease Study Cohort Technique Molecular Profile 
Local & Systemic Diseases 
[101] 
Wang et al.,  
Tumor Biol. 2014 
2 saliva data sets, 6 
plasma/serum data 
sets (meta-analysis) 
esophageal 
squamous cell 
carcinoma  
995 ESCC patients and 
733 healthy controls 
Bioinformatic and  
Statistics tools 
miR-144, miR-10, miR-451 
[102] 
Momen-Heravi et al.,  
J. Dent. Res. 2014 
CFS 
oral squamous 
cell carcinoma 
9 OSCC patients before 
treatment, 8 patients with 
OSCC in remission, and  
9 healthy controls 
NanoString nCounter 
miRNA expression assay 
(NanoString Technologies, 
Seattle, WA, USA) 
miRNA-136, miRNA-147, miRNA-1250, 
miRNA-148a, miRNA- 632, miRNA-646, 
miRNA668, miRNA- 877, miRNA-503, 
miRNA-220a, miRNA-323-5p, miRNA-24, 
miRNA-27b 
[103] 
Hizir et al.,  
ACS Appl. Mater. Interfaces 2014 
CFS 
prostate 
cancer 
NA nanographene oxide system miR-21, miR141 
[104] 
Gao et al.,  
BioMed. Res. Int. 2014 
CFS 
pancreatic 
cancer 
30 PC patients and  
32 healthy controls 
miScript miRNA PCR array 
human miRNome (384-well 
plate) (Qiagen) 
miR-17, miR-21, miR-181b, miR-196a 
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Table 1. Cont. 
Ref. Study Saliva Fraction Disease Study Cohort Technique Molecular Profile 
Forensic Science 
[79] 
Hanson et al.,  
Anal. Biochem. 2009 
WS 
body fluid 
identification 
Healthy donors (# NA) RTqPCR miR-658, miR-205 
[105] 
Zubakov et al.,  
Int. J. Legal. Med. 2010 
WS 
body fluid 
identification 
Healthy donors (# NA) 
Microarray LNATM-modified 
oligo-nucleotides (Exiqon, 
Vedbæk, Denmark),  
and RTqPCR 
miR-583, miR-518c*, miR-208b 
[106] 
Courts et al.,  
J. Forensic Sci. 2011 
WS 
body fluid 
identification 
Healthy donors (# NA) 
Microarray Geniom Biochips 
(Heidelberg, Germany)  
and RTqPCR 
miR-200c, miR-203, miR-205 
[107] 
Wang et al.,  
Forensic Sci. Int. Genet. 2012 
WS 
body fluid 
identification 
10 healthy donors RTqPCR miR-658, miR-205 
[108] 
Omelia et al.,  
Anal. Biochem. 2013 
WS 
body fluid 
identification 
6 healthy donors RTqPCR miR-205 
[109] 
Park JL et al.,  
Electrophoresis 2014 
WS 
body fluid 
identification 
60 healthy donors 
Affymetrix Gene Chip miRNA 
3.0 array and RTqPCR 
miR-203, miR-205 
[110] 
Silva et al.,  
Forensic Sci. Int. Genet. 2015 
– 
body fluid 
identification 
– – (Review) 
WS: whole saliva; CFS: cell free saliva; SP: saliva pellet and NA: not available. 
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2.3.1. Non-Coding RNAs for Local Diseases 
Several studies have been made with the aim of deciphering saliva miRNA profiles for oral cancer 
early diagnosis. In 2009, Park et al. [78], by comparing both CFS and WS from 12 healthy donors  
and a cohort of 50 cancer patients, found that miR-125a and miR-200a were differentially expressed  
in patients with oral cancer. In 2011, pursuing the same disease, Wiklund et al. [93] described a panel 
of miRNA and DNA methylation patterns. The panel, consisting of aberrant miR-375 and miR-200a 
expression and miR-200c-141 methylation, was initially found in oral squamous cell carcinoma 
(OSCC) tissues and then validated in oral rinse and saliva from OSCC patients and healthy controls, 
suggesting a potential clinical application for OSCC diagnosis. Later on, in 2012, Liu CJ et al. [94] 
described miR-31 as a clinical biomarker of OSCC in oral lesions, plasma, and saliva. They found 
miR-31 significantly increased in saliva from patients with oral carcinoma at all clinical stages, 
including very small tumors. However, no difference on salivary miR-31 expression was found when 
comparing patients with oral verrucous leukoplakia relative to controls. When comparing miR-31 
expression in different body fluids, they found that miR-31 was more abundant in saliva than in 
plasma, suggesting that salivary miR-31 was a more sensitive biomarker for oral malignancy. 
Furthermore, they also check the expression of miR-31 after excision of oral carcinoma, and found that 
salivary miR-31 was remarkably reduced, indicating that most of the up-regulated salivary miR-31 
came from tumor tissues. Interestingly, Matse et al. [95] have encountered that 95% of the differentially 
expressed miRNAs were over-expressed in saliva from patients with malignant tumors compared to 
those of patients with benign parotid gland tumors. A combination of four validated miRNAs was able 
to discriminate between cancerous and benign saliva, with a sensitivity of 69%, a specificity of 95%, 
and an area under the curve (AUC) of 0.9. 
More recently, Wang et al. [97], developed an electrochemical biosensor method for ultra-sensitive  
and specific detection of oral cancer-related miRNAs at attomolar levels. In order to evaluate the 
applicability of the novel RNA biosensor, saliva samples were spiked with different concentrations of 
target miRNAs (miR-200a, miR-142-3p, miR-93 and miR-125a). The results show clear indications  
that the magnetic-controllable electro-chemical biosensor had a strong resistance to the complex 
matrix of saliva, and therefore can be used to detect ultra-trace targeted miRNAs in real saliva samples 
with a recovery of 93%–108%. In 2013, Yang et al. [99] reported for the first time the use of miRNA  
microarray to profile low-grade dysplasia (LGD)-oral premalignant lesions (OPLs) from progressing and 
non-progressing LGD-OPLs, in order to explore the possible miRNAs that could lead the progression 
into high-grade dysplasia (HGD) or OSCC. Yang and colleagues identified 25 miRNAs differentially 
expressed between progressive and non-progressive LGD leukoplakias and, among them, 13 miRNAs 
were down-regulated and 12 miRNAs were up-regulated in progressive LGD leukoplakias. Moreover, 
Salazar et al. [100] concluded that miR-9, miR-191 and miR-134 can serve as novel non-invasive 
biomarkers in head and neck squamous cell carcinoma (HNSCC) (n = 122), providing a good 
discriminatory power with AUC values of 0.85 (p < 0.0001), 0.74 (p < 0.001) and 0.98 (p < 0.0001), 
respectively. In addition, their expression was independently validated using an HNSCC cohort 
consisting of 334 tumor samples and 39 normal adjacent tissues, curated in the TCGA database,  
showing a good correlation among tissue and saliva datasets. Finally, Momen-Heravi et al. [102] tested 
more than 700 miRNAs by using NanoString nCounter [111] in saliva samples from OSCC patients. 
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They identified 13 miRNAs that were differentially expressed in OSCC when compared to healthy 
controls and, among them, 11 miRNAs were down-regulated (miRNA-136, miRNA-147, miRNA-1250, 
miRNA-148a, miRNA-632, miRNA-646, miRNA-668, miRNA-877, miRNA-503, miRNA-220a, 
miRNA-323-5p), and two miRNAs were over-expressed (miRNA-24, miRNA-27b). 
Recently, a meta-analysis study was published addressing esophageal squamous cell carcinoma  
(ESCC) [101]. The study included six datasets from plasma/serum circulating miRNAs and two 
datasets from a saliva miRNA profile for ESCC; all datasets belong to previous studies published on 
the field [98,112]. Moreover, 17 studies, including 995 ESCC patients and 733 healthy controls, were 
included in the analysis. The meta-analysis showed a pooled AUC of 0.91 (95% CI 0.88–0.93).  
A sub-meta-analysis indicated that a blood-based miRNA assay displays better diagnostic accuracy  
than a saliva-based miRNA assay. Nevertheless, the individual study reported by Xie et al. [98],  
where the data for meta-analysis is derived from, showed that miR-10b*, miR-144, and miR-451 in 
WS, and miR-10b*, miR-144, miR-21, and miR-451 in CFS were significantly up-regulated in patients 
with ESCC, with sensitivities of 89.7%, 92.3%, 84.6%, 79.5%, 43.6%, 89.7%, and 51.3%, and 
specificities of 57.9%, 47.4%, 57.9%, 57.9%, 89.5%, 47.4%, and 84.2%, respectively, therefore 
demonstrating that saliva miRNAs possess discriminatory power for detection of ESCC. 
Most of the studies cited above described small ncRNAs, specifically miRNAs, the most common 
and exploited biomarkers found in saliva. However, there is only one study that describes long 
ncRNAs in saliva for oral cancer detection [96]. In this study, some of the detected long ncRNAs were 
aberrantly expressed in OSCC and metastatic tissues. Moreover, when checking the expression of 
these long ncRNAs in WS some of them appeared to be potential salivary biomarker candidates. 
Among several long ncRNAs investigated, MALAT-1 was present in all the patients investigated  
(n = 9), but HOTAIR was only detected in five out of nine patients with higher expression than in 
patients with lymph node metastasis. Taken together, this data indicates that WS contains a detectable 
amount of certain long ncRNAs that may be potential markers for OSCC diagnosis. 
2.3.2. Non-Coding RNAs for Systemic Diseases 
To our knowledge, there are only two studies that focused on salivary and circulating ncRNAs. 
Firstly, Hizir M.S. and colleagues [103] evaluated the expression of miR-21 and miR-141, two 
miRNAs over-expressed in early and advanced prostate cancer patients, respectively. They have 
demonstrated simultaneous detection of endogenous and exogenous miR-21 and miR-141 from human 
body fluids including blood, urine, and saliva, by using a specially designed biosensing nanographene 
oxide system, which uses two different wavelengths to detect miR-21 and miR-141 simultaneously 
(520 and 670 nm, respectively). Their approach is faster and easier than multiple and simultaneous 
qPCR detection, and can be performed with a portable spectrofluorometer; however, the sensitivity 
needs to be improved for clinical application. Secondly, Gao et al. [104] described a three-miRNA 
panel (miR-17, miR-21, and miR-181b) in CFS that improves the current techniques of traditional 
Chinese medicine (TCM) to diagnose pancreatic cancer. A cohort of 62 patients was subsequently 
confirmed by a larger cohort based on several online databases. Thus, these studies represent the 
beginning of the salivary small ncRNAs’ utility to diagnose systemic diseases through a non-invasive 
method. However, no study has been published in the field of salivary long ncRNAs and non-oral 
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diseases. Since there is much evidence that long ncRNAs can serve as circulating diagnostic 
biomarkers for several diseases, like B-cell neoplasms and prostate cancer [113–115], and also that 
those long ncRNAs have sufficient power to discriminate between cancer and healthy status [96,116], 
we truly believe that it is just a matter of time before long (and short) ncRNAs will appear as the new 
spectrum of diagnostic biomarkers in saliva, specific for local and systemic diseases, reaching the 
same position as transcriptomics and proteomics, which are currently leading in salivary diagnostics. 
2.4. Forensic Science and Body Fluid Identification 
Forensic scientists are interested in detecting the presence of tissue-specific mRNAs in dried  
body fluid stains, including saliva, as a means of positively identifying the tissue source of origin of  
a physiologic stain recovered from a crime scene [79,117–119]. They have not expressly determined 
whether the varieties of mRNA species that are routinely detected in saliva originate from the cellular 
or non-cellular fractions of saliva because, in a forensic context, the cellular vs. non-cellular source is 
immaterial. Nevertheless, the presence of mRNA species in WS is irrefutable and they routinely isolate 
mRNA of sufficient quality and quantity [117] for routine RT-PCR and RT-qPCR analyses. The 
persistence and stability was such that they could detect and analyze mRNA from small quantities of 
dried saliva stains collected weeks or even months after the initial deposition. They have identified  
a number of candidate tissue-specific genes (statherin, histatin 3, PRM1, PRM2), which may be useful 
for the positive identification of saliva. mRNAs from these genes were detectable in saliva stains but 
not in blood or semen stains [117,118]. Collectively these findings constitute the basis of a prototype 
RNA-based assay system that may eventually supplant conventional methods for body fluid identification. 
In addition to the efforts devoted to look for forensic salivary mRNA, several studies have been 
recently focused on ncRNAs following the same purpose. The size of the amplification products used  
in the mRNA assays (>200–300 nt) might not be ideal to use with degraded or compromised samples 
frequently encountered in forensic casework. Therefore, there has been an explosion of interest in  
a class of small ncRNAs: miRNA. Hanson et al. [79] provided the first comprehensive evaluation of 
miRNA expression in dried, forensically relevant biological fluids—blood, semen, saliva, vaginal 
secretions, and menstrual blood—in an attempt to identify putative body fluid-specific miRNAs. They 
have identified a panel of nine miRNAs—miR-451, miR-16, miR-135b, miR-10b, miR-124a, miR-372, 
and miR-412, miR-658, miR-205 (being the last two specific of saliva)—that are differentially 
expressed to such a degree as to permit the identification of the body fluid origin of forensic biological 
stains using as little as 50 pg of total RNA. Courts et al. [106] and Park et al. [109], after microarray 
analysis, also validate by RT-qPCR one of the selected miRNAs that Hanson and colleagues found 
specific to saliva body fluid identification. Conversely, Zubakov et al. [105] have selected a total of  
14 most promising biomarkers derived from a microarray data analysis for validation in TaqMan-based 
RT-qPCR assays, but they did not find a correlation between their microarray data and RT-qPCR 
expression analyses for saliva, vaginal secretions, and menstrual blood. The failure to include all 
forensically important body fluids in genome-wide miRNA profiling may be a cause for discrepancy 
among these studies [109]. Apart from that, Wang et al. [107] created an efficiency-calibrated model 
that incorporated the impact of the quantification cycle (Cq) values and PCR efficiencies of target and 
reference genes to calculate the relative expression ratio of miRNAs in forensically relevant body 
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fluids, suggesting that miR-658 and miR-205 were non-specific for saliva among the other forensically 
tested body fluids. Furthermore, Omelia et al. [108] confirmed that it is possible to detect miR-205 in 
saliva samples that were previously extracted using standard DNA extraction protocols, suggesting the 
usefulness of these previously tested forensic samples. Considering all of the above, Silva et al. [110], 
very recently reviewed the multiple factors that have the potential likelihood of discrediting miRNA 
profiling, and highlight the ultimate question whether miRNA profiling can be used or not as the forensic 
biomarkers for body fluid identification. 
3. Salivary Non-Coding RNAs as a Diagnostic Test Tool 
The utility of saliva as a diagnostic tool, which provides a non-invasive, easy, and low-cost method 
for disease detection and screening, has been reviewed elsewhere [120]. Saliva collection is more 
practical and comfortable compared with other invasive methods, and that is one of the main reasons 
that make saliva a desirable body fluid for clinical applications, with particular interest in large 
population screening, children, geriatric patients, and in cases where repeated samplings are needed.  
The growth of the knowledge in constituents within saliva has helped the rapid and accurate detection 
and quantification of its molecules, allowing researchers to discover, develop, and validate biomarkers 
for detection of several diseases. Thus, clinical salivaomics has much more promise in medicine with 
cutting-edge omic technologies combined with advanced bioinformatics. However, without proper 
study design and implementation of robust analytical techniques, the efforts and expectations may very 
easily be hampered. 
Saliva is a proximal body fluid in the oral cavity and therefore is intuitively sound for detection of 
oral diseases. However, this increasingly used body fluid has been recently termed “liquid biopsy”, 
useful to detect non-oral diseases [51,55–62]. Some studies hypothesize that molecules can travel from 
the primary tumor to the blood and appear altered in cancer compared to control saliva. Gao et al. [55] 
used induced tumor bearing mice models of melanoma and lung cancer and defined a salivary 
transcriptome profile associated to each tumor-type. Lau et al. [59], by using a pancreatic tumor-bearing 
mice model, revealed the basic mechanisms underlying the rationale of salivary biomarkers through 
the hypothesis that exosome-like vesicles carry, drive, and deliver tumor markers into the saliva. The 
lack of clear mechanisms showing how salivary biomarkers can reflect disease states elsewhere in the 
body has compromised the scientific acceptance of this emerging field [28]. Although several hypotheses 
have been proposed, the mechanistic underpinning awaits validation [28]. The clinical and scientific 
credentialing of saliva for systemic disease detection will present a groundbreaking technology, 
impactful and sustainable, that will transform molecular diagnostics globally. 
As previously mentioned, whilst several efforts have been made to characterize small ncRNAs in 
saliva, there is no such information for long ncRNAs. There is a necessity to improve standardized 
protocols for long ncRNA isolation, data analysis, and bioinformatics pipelines that yield better quality 
of starting materials and significant data, which will therefore allow characterization and good quality 
outcomes. Thus, the emerging interest in the field and the recent publications revealing new ncRNAs  
in saliva, including miRNAs, piRNAs, and circRNAs, may be, in the near future, the basis for future 
biomarker discoveries. 
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4. Conclusions and Future Perspectives 
ncRNAs profiles in human diseases, especially in cancer, have highlighted the potential value of 
this class of RNAs as disease-related biomarkers for patient diagnosis. The rapidly expanding and 
continuous cataloging of salivary ncRNAs holds promises that, in the near future (Figure 1), ncRNAs 
will become even more important in disease–patient management. An analogy can be made with  
the impact of salivary mRNA profiling in many types of disease, which has provided different 
experimental lines of evidence that deregulation of mRNAs not only results as a consequence of cancer 
progression, but also directly affects gene networks that promote tumor initiation and progression in  
a cause–effect manner. 
As the catalog of salivary ncRNAs grows, it will become important to elucidate the genetic 
networks and pathways regulated by the abnormally expressing ncRNAs in saliva from cancer patients 
as a means to understand the role and biomarker performance of these ncRNAs in the induction of 
malignant transformation, as well as their ability to create significant profiles for salivary diagnostics. 
In summary, ncRNAs profiles could have an impactful applicability to clinical practice by meeting the 
demand for an inexpensive, non-invasive, and accessible diagnostic tool. 
 
Figure 1. The rise of non-coding RNA in saliva. 
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